The company reported a significant financial turnaround for the third quarter, posting earnings of 3 cents per share on record sales of $211 million. This marks a stark departure from the same period last year, when the firm recorded a loss of 28 cents per share on $133.5 million in revenue.

Driving the current market optimism is a substantial revision to the company’s future revenue targets. Glaukos lifted its 2026 net sales guidance to a range of $775 million to $785 million, up from the previous estimate of $680 million to $700 million. Looking further ahead, management introduced a preliminary 2027 net sales target of $1 billion. Glaukos continues to focus its portfolio on ophthalmic pharmaceuticals and medical devices designed to treat glaucoma, corneal disorders, and retinal diseases.